Targeted mutation-based therapy for intrahepatic cholangiocarcinoma

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive primary liver cancer with limited treatment options and poor prognosis. Although gemcitabine combined with cisplatin (GEMCIS) or newly GEMCIS plus durvalumab is the first-line systemic therapy for iCCA, several promising treatment targets have been identified in the past decade in both first- and subsequent-line settings, including neurotrophic tropomyosin-receptor tyrosine kinase (NTRK) fusions, RET fusions, high microsatellite instability (MSI-H), high tumor mutation burden (TMB-H), as well as fibroblast growth factor receptor 2 (FGFR2) fusions, BRAF V600E mutation, isocitrate dehydrogenase (IDH)-1 and IDH-2 mutations, and human epidermal growth factor receptor 2 [HER2 (ERBB2)] amplifications. Corresponding small molecule inhibitors and monoclonal antibodies have demonstrated improved efficacy and survival benefits in phase 2 or phase 3 studies, gained regulatory approvals or recommendations in guidelines, and reshaped the therapeutic management for advanced cholangiocarcinoma. Numerous novel targeted drugs and combination therapies have been developed and are under evaluation. Despite the progress made in targeted therapy, it still faces challenges such as acquired drug resistance, precise patient selection, and serious adverse events. Therefore, large-scale randomized phase 3 trials of novel targeted agents and innovative regimens are warranted to benefit this population. Herein, we present a comprehensive review of the literature of clinical significance on targeted therapy for iCCA in recent years, focusing on the advances in mutation-based targeted therapy.

Keywords

Intrahepatic cholangiocarcinoma / genomic alterations / genetic landscape / targeted therapy

References

[1] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[2] Endo I,Yopp AC.Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.Ann Surg2008;248:84-96

[3] Moris D,Kim C,Morse MA.Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians.CA Cancer J Clin2023;73:198-222.

[4] Bekaii-saab T,Normanno N.Practical considerations in screening for genetic alterations in cholangiocarcinoma.Ann Oncol2021;32:1111-26

[5] Lamarca A,McNamara MG.Molecular targeted therapies: ready for "prime time" in biliary tract cancer.J Hepatol2020;73:170-85

[6] Hoy SM.Pemigatinib: first approval.Drugs2020;80:923-9

[7] Goyal L,Hollebecque A.FOENIX-CCA2 Study InvestigatorsFutibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma.N Engl J Med2023;388:228-39

[8] Kendre G,Brummer T,Saborowski A.Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.J Hepatol2023;78:614-26

[9] Verdaguer H,Acosta DA.ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma.Clin Cancer Res2022;28:1662-71

[10] Wang XY,Wang Z.Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.Theranostics2022;12:260-76 PMCID:PMC8690927

[11] Carapeto F,Shroff RT.The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.Hepatology2022;75:297-308 PMCID:PMC8766948

[12] Cleary JM,Wu Q.FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma.Cancer Discov2021;11:2488-505

[13] Lowery MA,Jordan E.Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention.Clin Cancer Res2018;24:4154-61 PMCID:PMC6642361

[14] Jusakul A,Yong CH.Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma.Cancer Discov2017;7:1116-35. PMCID:PMC5628134

[15] Verlingue L,Boige V,Malka D.Matching genomic molecular aberrations with molecular targeted agents: are biliary tract cancers an ideal playground?.Eur J Cancer2017;81:161-73

[16] Weinberg BA,Lindberg MR.Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.J Gastrointest Oncol2019;10:652-62 PMCID:PMC6657312

[17] Zhang Y,Li C.The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers.Nat Commun2022;13:3061. PMCID:PMC9160072

[18] Komuta M.Intrahepatic cholangiocarcinoma: tumour heterogeneity and its clinical relevance.Clin Mol Hepatol2022;28:396-407 PMCID:PMC9293614

[19] Song G,Meng L.Publisher correction: single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma.Nat Commun2022;13:2848 PMCID:PMC9114109

[20] Dong L,Chen R.Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.Cancer Cell2022;40:70-87.e15.

[21] Dentro SC,Haase K.PCAWG Evolution and Heterogeneity Working Group and the PCAWG ConsortiumCharacterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes.Cell2021;184:2239-54.e39. PMCID:PMC8054914

[22] Lin Y,Dong L.Geospatial immune heterogeneity reflects the diverse tumor-immune interactions in intrahepatic cholangiocarcinoma.Cancer Discov2022;12:2350-71

[23] Xiang X,Zhang C.IDH mutation subgroup status associates with intratumor heterogeneity and the tumor microenvironment in intrahepatic cholangiocarcinoma.Adv Sci2021;8:e2101230 PMCID:PMC8425914

[24] Lin J,Sang C.Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.J Immunother Cancer2022;10:e004892 PMCID:PMC9310257

[25] Farrell B.Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting.Biochem Soc Trans2018;46:1753-70 PMCID:PMC6299260

[26] Wiedemann M.Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors.Genomics2000;69:275-9

[27] Helsten T,Arthur E,Carter J.The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing.Clin Cancer Res2016;22:259-67

[28] Abou-Alfa GK,Hollebecque A.Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol2020;21:671-84 PMCID:PMC8461541

[29] Shi GM,Wen TF.Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: a phase II study.Cancer Med2023;12:4137-46 PMCID:PMC9972033

[30] NCCN. NCCN Guidelines. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517 [Last accessed on 14 Nov 2023]

[31] Javle M,Kelley RK.Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Lancet Gastroenterol Hepatol2021;6:803-15

[32] Borad M,Shaib W.59P efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications.Ann Oncol2022;33:S567-8

[33] Ward PS,Wise DR.The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Cancer Cell2010;17:225-34 PMCID:PMC2849316

[34] Dang L,Gross S.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.Nature2009;462:739-44 PMCID:PMC2818760

[35] Bleeker FE,Lamba S.The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.Acta Neuropathol2010;119:487-94 PMCID:PMC2841753

[36] Pirozzi CJ.The implications of IDH mutations for cancer development and therapy.Nat Rev Clin Oncol2021;18:645-61

[37] Yang Z,Wang Y.2-HG inhibits necroptosis by stimulating DNMT1-dependent hypermethylation of the RIP3 promoter.Cell Rep2017;19:1846-57

[38] Fujiwara H,Misumi K.Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.Sci Rep2019;9:18859 PMCID:PMC6906335

[39] Wu MJ,Dubrot J.Mutant IDH Inhibits IFNγ-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma.Cancer Discov2022;12:812-35 PMCID:PMC8904298

[40] Chen X,Qiao Y.Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2.Sci Rep2022;12:18830. PMCID:PMC9637083

[41] Wintheiser G,Shi Q.Isocitrate dehydrogenase-mutated cholangiocarcinoma: natural history and clinical outcomes.JCO Precis Oncol2022;6:e2100156

[42] Wang J,Ding ZY.IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC.J Surg Res2018;231:116-25.

[43] Jiao Y,Anders RA.Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.Nat Genet2013;45:1470-3 PMCID:PMC4013720

[44] Wang P,Zhang C.Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.Oncogene2013;32:3091-100 PMCID:PMC3500578

[45] Goyal L,Sheth RA.Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma.Oncologist2015;20:1019-27 PMCID:PMC4571807

[46] Jolissaint JS,Seier KP.Intrahepatic cholangiocarcinoma with lymph node metastasis: treatment-related outcomes and the role of tumor genomics in patient selection.Clin Cancer Res2021;27:4101-8 PMCID:PMC8282702

[47] Niger M,Casadei-Gardini A.Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: a propensity score-based study.Int J Cancer2022;151:1310-20

[48] Abou-Alfa GK,Javle MM.Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020;21:796-807. PMCID:PMC7523268

[49] Levantini E,Del Re M.EGFR signaling pathway as therapeutic target in human cancers.Semin Cancer Biol2022;85:253-75.

[50] Hsu JL.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.Cancer Metastasis Rev2016;35:575-88 PMCID:PMC5215954

[51] Kumagai S,Nishikawa H.Antitumour immunity regulated by aberrant ERBB family signalling.Nat Rev Cancer2021;21:181-97

[52] Treekitkarnmongkol W.High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.World J Gastroenterol2010;16:4047-54 PMCID:PMC2928458

[53] Swain SM,Hamilton E.Targeting HER2-positive breast cancer: advances and future directions.Nat Rev Drug Discov2023;22:101-26. PMCID:PMC9640784

[54] Javle M,Azad NS.Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol2021;22:1290-300

[55] Ohba A,Kawamoto Y.Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).JCO2022;40:4006

[56] Harding JJ,Shah RH.Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.Nat Commun2023;14:630. PMCID:PMC9902444

[57] Meric-Bernstam F,Hamilton E.Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.Lancet Oncol2022;23:1558-70

[58] Sithanandam G,Cannizzaro LA,Huebner K.B-raf and a B-raf pseudogene are located on 7q in man.Oncogene1992;7:795-9

[59] Davies H,Cox C.Mutations of the BRAF gene in human cancer.Nature2002;417:949-54

[60] Robertson S,Dodson R.The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.Hum Pathol2013;44:2768-73 PMCID:PMC3838441

[61] Iversen L,Lin WC.Molecular kinetics. Ras activation by SOS: allosteric regulation by altered fluctuation dynamics.Science2014;345:50-4.

[62] Huang L,Wang F.KRAS mutation: from undruggable to druggable in cancer.Signal Transduct Target Ther2021;6:386 PMCID:PMC8591115

[63] Zhu C,Zhang X.Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Mol Cancer2022;21:159 PMCID:PMC9351107

[64] Parikh K,Liu SV.Drugging KRAS: current perspectives and state-of-art review.J Hematol Oncol2022;15:152 PMCID:PMC9597994

[65] Subbiah V,Élez E.Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Lancet Oncol2020;21:1234-43

[66] Salama AKS,Macrae ER.Dabrafenib and trametinib in patients with tumors with BRAF^V600E mutations: results of the NCI-MATCH trial subprotocol H.J Clin Oncol2020;38:3895-904 PMCID:PMC7676884

[67] Subbiah V,Blay JY.Pan-cancer efficacy of vemurafenib in BRAF^V600-mutant non-melanoma cancers.Cancer Discov2020;10:657-63. PMCID:PMC7196502

[68] Kim JW,Kim JW.Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study.Br J Cancer2019;121:332-9. PMCID:PMC6738070

[69] Subbiah V,Siena S.Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.Nat Med2022;28:1640-5 PMCID:PMC9388374

[70] Subbiah V,Konda B.Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.Lancet Oncol2022;23:1261-73

[71] Cocco E,Drilon A.NTRK fusion-positive cancers and TRK inhibitor therapy.Nat Rev Clin Oncol2018;15:731-47 PMCID:PMC6419506

[72] Yoshino T,Mishima S.JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.Ann Oncol2020;31:861-72

[73] Vaishnavi A,Doebele RC.TRKing down an old oncogene in a new era of targeted therapy.Cancer Discov2015;5:25-34 PMCID:PMC4293234

[74] Scott LJ.Larotrectinib: first global approval.Drugs2019;79:201-6.

[75] Hong DS,Kummar S.Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol2020;21:531-40 PMCID:PMC7497841

[76] Demetri GD,Drilon A.Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors.Clin Cancer Res2022;28:1302-12. PMCID:PMC9365368

[77] Marcus L,Keegan P.FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors.Clin Cancer Res2019;25:3753-8

[78] Richman S.Deficient mismatch repair: read all about it (review).Int J Oncol2015;47:1189-202 PMCID:PMC4583524

[79] Jung J,Park S.High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.J Immunother Cancer2023;11:e006454 PMCID:PMC10152061

[80] Le DT,Smith KN.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science2017;357:409-13.

[81] Borghaei H,Lee JS.Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.Ann Oncol2023;34:173-85

[82] Maio M,Manzyuk L.Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.Ann Oncol2022;33:929-38

[83] Andre T,Curigliano G.Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study.JCO2021;39:9

[84] Schenker M,Richardet M.Abstract CT022: checkMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.Cancer Res2022;82:CT022

[85] Kim RD,Alese OB.A Phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer.JAMA Oncol2020;6:888-94. PMCID:PMC7193528

[86] Oh DY,Qin S.Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.NEJM Evid2022;1:EVIDoa2200015

[87] Kelley RK,Yoo C.KEYNOTE-966 InvestigatorsPembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2023;401:1853-65.

[88] Mosele F,Mateo J.Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group.Ann Oncol2020;31:1491-505.

[89] Marchiò C,Ladanyi M.ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.Ann Oncol2019;30:1417-27

[90] Graham RP,Pestova E.Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.Hum Pathol2014;45:1630-8.

[91] Rompianesi G,Gordon-Weeks A,Troisi R.Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.World J Gastrointest Oncol2021;13:332-50 PMCID:PMC8131901

[92] Berchuck JE,DiToro DF.The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.Ann Oncol2022;33:1269-83

[93] Goyal L,Liu LY.TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.Cancer Discov2019;9:1064-79

[94] Sootome H,Ito K.Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors.Cancer Res2020;80:4986-97

[95] Calvert AE,Wu Y.Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation.Cell Rep2017;19:1858-73 PMCID:PMC5564207

[96] Intlekofer AM,Wang B.Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.Nature2018;559:125-9 PMCID:PMC6121718

[97] Harding JJ,Shih AH.Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition.Cancer Discov2018;8:1540-7 PMCID:PMC6699636

[98] Lito P,Solit DB.Tumor adaptation and resistance to RAF inhibitors.Nat Med2013;19:1401-9

[99] Mazzaferro V,Droz Dit Busset M.Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.Br J Cancer2019;120:165-71 PMCID:PMC6342954

[100] Bahleda R,Hierro C.Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors.Clin Cancer Res2019;25:4888-97

[101] Kim SB,Kalyan A.First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer.Target Oncol2019;14:591-601. PMCID:PMC6797631

[102] Ahn DH,Masci P.A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.Invest New Drugs2022;40:134-41

[103] Lee CK,Cheon J.Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).Lancet Gastroenterol Hepatol2023;8:56-65